Ocular Therapeutix reported a net loss of $13.8 million, or $0.40 per share, in the first quarter of 2018 compared with a net loss of $16 million, or $0.58 per share, in 2017’s first quarter, according to a press release.
The company posted $340,000 in revenue in the quarter from sales of ReSure sealant compared with $475,000 in 2017’s first quarter.
Research and development costs increased from $6.8 million to $8.2 million, led by expenses for development of the company’s hydrogel platform technology and portfolio of drug product candidates. General (Read more...)
Uncategorized